Suven Pharmaceuticals Ltd, a global Contract Development and Manufacturing Organisation (CDMO), announced its Q2 and H1 FY25 financial results on November 12, 2024.
The company achieved revenue of ₹258 crore for Q2, marking a 12% year-on-year (YoY) growth, while gross margins expanded by 473 basis points, driven by a favourable business mix and the consolidation of its recently acquired oligonucleotide segment. Adjusted EBITDA reached ₹112 crore, with an EBITDA margin of 43.3%.
Suven expects to meet its full-year growth projections, with accelerated growth anticipated from FY26 onward.
Mr Vivek Sharma, Executive Chairman, said, “There is a strong momentum favouring the CDMO sector, with India as the biggest beneficiary driven by efforts to diversify supply chains, along with supportive macroeconomic trends like the potential US Biosecure Act. Suven, with its strong track record and extensive offerings, continues to be committed to offering its customers a tech-led end-to-end CDMO platform.”
On November 13, 2024, Suven Pharmaceuticals share price opened at ₹1,220.00, touching the day high of ₹1,269.75 as of 10:08 AM on NSE.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
We're Live on WhatsApp! Join our channel for market insights & updates
Enjoy ₹0 Account Opening Charges
Join our 2 Cr+ happy customers